Annual Meeting of Shareholders June 13, 2023 / Availability of preparatory documents
Annual Meeting of ShareholdersJune 13, 2023
Availability of preparatory documents
Paris, France, May24, 2023 – 19:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, informs its shareholders that its Annual Meeting of the Company will be held on June 13, 2023, at 2.00 pm CET at the headquarter of Pixium Vision, 74 rue du faubourg Saint Antoine in Paris (75012).
The prior notice of the Annual Meeting of Shareholders containing the agenda, the draft resolutions presented by the Board of Directors for agreement by the shareholders was published in the BALO n°55 (Bulletin des Annonces Légales Obligatoires) on May 8, 2023 and the convening notice that was published in the BALO n°62 on May 24, 2023 as well as in the Affiches Parisiennes (legal newspapers).
As of today the information regarding the Combined General Meeting mentioned in article R. 225-83 of the French commercial Code can be found on the Company’s website www.pixium-vision.com, under «Investors», « Shareholder’s General Meeting”.
The documents and information mentioned in articles R.225-81 and R.225-83 of the French commercial Code can be sent to shareholders upon request to the Company.
Shareholders will also be able to consult the documents at the Company’s registered office located in Paris (75012), 74, rue du Faubourg Saint Antoine, during 15 days prior to the Combined General Meeting.
About Pixium Vision
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2022 Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- france.org) or on the Company’s website.
For more information: http://www.pixium-vision.com/fr
Follow us on @PixiumVision; www.facebook.com/pixiumvision
|Media Relations |
Rose Piquante Consulting
+33 6 27 74 74 49
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock5.6.2023 23:30:00 CEST | Press release
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in initial gross proceeds of $28.0 million to Telesis Bio. The warrants issued in the private placement will provide Telesis Bio with approximately $46.2 million in additional gross proceeds if they are cash exercised. The financing was led by Novalis LifeSciences LLC with participation from Northpond Ventures, BroadOak Capital Partners and M-185 Corporation, an affiliate of the Company’s Chief Executive Officer and Founder, Todd R. Nelson, PhD. The Company also announced the appointment of Paul Meister, a partner at Novalis LifeSciences LLC, to the Company’s board of directors immediately following the closing. Please refer to the Company’s Form 8-K to be filed with the Securities and Exchang
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress5.6.2023 22:01:00 CEST | Press release
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter’s Transformation (RT), responded to treatment (Objective Response Rate of 100%)1 GLPG5201 showed no cytokine release syndrome (CRS) higher than grade 2, or immune effector cell-associated neurotoxicity syndrome (ICANS)2 A functionally closed, automated manufacturing platform for cell therapies at the point-of-care will be shown at the Galapagos booth A.103at the EHA 2023 congress Mechelen, Belgium; 5 June 2023,22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature theCAR-T point-of-care manufacturing platform and willpresent previously disclosed initial Phase 1/2 data with CD19 CAR-T candidate, GLPG5201, at the European Hematology Association (EHA) 2023 congress, taking place from 8 June to 11June 2023 in Frankfurt, Germany. “Patients who develop rrCLL and become resistant to new agents have a very poor prognosis and a significant high
Hoylu AB: Publicerar årsredovisning för 20225.6.2023 21:15:00 CEST | Pressemelding
Hoylu AB (publ) meddelar idag att årsredovisningen för räkenskapsåret 2022 bifogas detta pressmeddelande och finns tillgänglig på bolagets hemsida: (https://www.hoylu.com/investor-relations/financial-reports/). För mer information kontakta: Truls Baklid, CEO, +47 924 38 900 Email: email@example.com Karl Wiersholm, CFO, +1 425 829 2316 Email: firstname.lastname@example.org Om Hoylu Hoylus uppdrag är att ge distribuerade team möjlighet att samarbeta enkelt och sömlöst samtidigt som de alltid håller sig synkroniserade. Hoylus Adaptive Workspaces™ hjälper företag såväl stora som små att driva projekt, program och initiativ över olika tidszoner och kontinenter med samma engagemang och tydlighet som om alla arbetade i samma rum. För mer information: www.hoylu.com Kortnamn: Hoylu Marknadsplats: Nasdaq First North Growth Stockholm Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550; email@example.com Publicering Informationen lämnades, genom ovanstående kontaktpersons försorg för offentliggörande den 5 ju
Hoylu AB: Publishes its Annual Report for 20225.6.2023 21:15:00 CEST | Press release
Hoylu AB (publ) announced today that the Annual Report for 2022 is attached to this press release and is available on Hoylu's web site: (https://www.hoylu.com/investor-relations/financial-reports/). For more information contact: Truls Baklid, CEO, +47 924 38 900 Email: firstname.lastname@example.org Karl Wiersholm, CFO, +1 425 829 2316 Email: email@example.com About Hoylu Hoylu’s visual collaboration technology empowers distributed teams to translate ideas into actions. Large enterprises as well as small and medium companies rely on Hoylu to run projects, programs, and initiatives across time zones and continents as seamlessly as when working in the same room. For more information: www.hoylu.com Try Hoylu for free: https://app.hoylu.com/ Ticker symbol: Hoylu Marketplace: Nasdaq First North Growth Market Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550, firstname.lastname@example.org Publication The information was submitted for publication, through the agency of the contact person set out above, at 21:15 CE
Nokia Corporation: Repurchase of own shares on 05.06.20235.6.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 5 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 05.06.2023 Espoo, Finland – On 5 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL308,5933.85CEUX48,4053.86AQEU4,7293.86TQEX3,3733.87Total365,1003.86 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and en